Bioxyne Limited
Bioxyne Limited Fundamental Analysis
Bioxyne Limited (BXN.AX) shows moderate financial fundamentals with a PE ratio of 15.89, profit margin of 18.23%, and ROE of 56.29%. The company generates $0.0B in annual revenue with weak year-over-year growth of 2.26%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 80.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze BXN.AX's fundamental strength across five key dimensions:
Efficiency Score
ExcellentBXN.AX demonstrates superior asset utilization.
Valuation Score
ExcellentBXN.AX trades at attractive valuation levels.
Growth Score
WeakBXN.AX faces weak or negative growth trends.
Financial Health Score
ExcellentBXN.AX maintains a strong and stable balance sheet.
Profitability Score
ModerateBXN.AX maintains healthy but balanced margins.
Key Financial Metrics
Is BXN.AX Expensive or Cheap?
P/E Ratio
BXN.AX trades at 15.89 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, BXN.AX's PEG of 0.21 indicates potential undervaluation.
Price to Book
The market values Bioxyne Limited at 7.06 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 14.98 times EBITDA. This signals the market has high growth expectations.
How Well Does BXN.AX Make Money?
Net Profit Margin
For every $100 in sales, Bioxyne Limited keeps $18.23 as profit after all expenses.
Operating Margin
Core operations generate 18.68 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $56.29 in profit for every $100 of shareholder equity.
ROA
Bioxyne Limited generates $25.89 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bioxyne Limited generates limited operating cash flow of $2.04M, signaling weaker underlying cash strength.
Free Cash Flow
Bioxyne Limited generates weak or negative free cash flow of $-62.67K, restricting financial flexibility.
FCF Per Share
Each share generates $-0.00 in free cash annually.
FCF Yield
BXN.AX converts -0.04% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
15.89
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.21
vs 25 benchmark
P/B Ratio
Price to book value ratio
7.06
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.92
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.37
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.79
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.56
vs 25 benchmark
ROA
Return on assets percentage
0.26
vs 25 benchmark
ROCE
Return on capital employed
0.38
vs 25 benchmark
How BXN.AX Stacks Against Its Sector Peers
| Metric | BXN.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 15.89 | 22.37 | Better (Cheaper) |
| ROE | 56.29% | 1250.00% | Weak |
| Net Margin | 18.23% | -5215.00% (disorted) | Strong |
| Debt/Equity | 0.37 | 1.23 | Strong (Low Leverage) |
| Current Ratio | 2.79 | 2.47 | Strong Liquidity |
| ROA | 25.89% | -193095.00% (disorted) | Strong |
BXN.AX outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bioxyne Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
301.02%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthEPS CAGR
346.09%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
3773.86%
Industry Style: Defensive, Dividend, Low Volatility
High Growth